Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

39.95
-0.1500-0.37%
Pre-market: 40.140.1900+0.48%04:10 EDT
Volume:587.80K
Turnover:23.31M
Market Cap:3.85B
PE:-20.42
High:40.20
Open:39.85
Low:38.90
Close:40.10
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.74
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.21
PE(LYR):-31.09

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa

Reuters
·
Apr 06

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Apr 06

BUZZ-IDEAYA Biosciences rises as early-stage cancer trial starts

Reuters
·
Apr 06

IDEAYA enrolls first patient in Phase 1 trial of KAT6/7 inhibitor IDE574

Reuters
·
Apr 06

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide574, a Potential First-in Class Dual Inhibitor of Kat6/7 to Target Multiple Solid Tumor Indications, Including Breast, Prostate, Crc, and Lung Cancer

THOMSON REUTERS
·
Apr 06

Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?

Simply Wall St.
·
Apr 04

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow Jones
·
Mar 31

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco

Reuters
·
Mar 30

BUZZ-Ideaya rises as it starts early-stage trial of combination of cancer drugs

Reuters
·
Mar 30

IDEAYA starts Phase 1 trial of IDE849-IDE161 combo in DLL3 solid tumors

Reuters
·
Mar 30

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Combination Study of Ide849, Dll3 Top1 ADC, and Ide161, Parg Inhibitor, in Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, and Melanoma

THOMSON REUTERS
·
Mar 30

IDEAYA Biosciences Inc - Targets Clinical Data Update for Ide849 and Ide161 in H2 2026

THOMSON REUTERS
·
Mar 30

Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 28